¼¼°èÀÇ Æó¾Ï ¼ö¼ú ½ÃÀå
Lung Cancer Surgery
»óǰÄÚµå : 1559556
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 279 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,301,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,905,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Æó¾Ï ¼ö¼ú ¼¼°è ½ÃÀåÀº 2030³â±îÁö 83¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù

2023³â 62¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Æó¾Ï ¼ö¼ú ¼¼°è ½ÃÀåÀº 2023-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È ¿¬Æò±Õ 4.2% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 83¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Èä°­°æ ¼ö¼úÀº CAGR 4.1%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 58¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÃÖ¼Ò Ä§½À ¼ö¼ú ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 17¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.5%·Î ¼ºÀå Àü¸Á

¹Ì±¹ÀÇ Æó¾Ï ¼ö¼ú ½ÃÀåÀº 2023³â 17¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 18¾ï ´Þ·¯ ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È 6.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 2.7%¿Í 3.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¿¬Æò±Õ 3.3%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è Æó¾Ï ¼ö¼ú ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

Æó¾Ï ¼ö¼úÀÌ ¿À´Ã³¯ ¾Ï Ä¡·á¿¡¼­ Áß¿äÇÑ ¿ä¼ÒÀÎ ÀÌÀ¯´Â ¹«¾ùÀϱî?

Æó¾ÏÀº ¿©ÀüÈ÷ ¼¼°è¿¡¼­ °¡Àå ³Î¸® ÆÛÁ® ÀÖ°í Ä¡¸íÀûÀÎ ¾Ï Áß ÇϳªÀ̸ç, ¼ö¼ú°ú °°Àº È¿°úÀûÀÎ Ä¡·á¹ýÀÌ ÀÌ Áúº´°úÀÇ ½Î¿ò¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Æó¾Ï ¼ö¼úÀº Á¾¾ç°ú ¾Ï¼¼Æ÷°¡ ÆÛÁ® ÀÖÀ» ¼ö ÀÖ´Â ÁÖº¯ Æó Á¶Á÷À» Á¦°ÅÇÕ´Ï´Ù. ÀÌ ¹æ¹ýÀº ÀϹÝÀûÀ¸·Î Á¾¾çÀÌ ±¹ÇѵǾî ÀÖ°í ¼ö¼úÀÌ °¡´ÉÇÑ Æó¾Ï, ƯÈ÷ ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC)ÀÇ Ãʱ⠴ܰ迡¼­ °¡Àå È¿°úÀûÀÔ´Ï´Ù. ºñµð¿À º¸Á¶ ÈäºÎ ¼ö¼ú(VATS)À̳ª ·Îº¿ º¸Á¶ ¼ö¼ú°ú °°Àº ÃÖ¼Ò Ä§½À ¼ö¼ú µî ¼ö¼ú ±â¹ýÀÇ ¹ßÀüÀ¸·Î ȯÀÚ ¿¹Èİ¡ Å©°Ô °³¼±µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¼úÀº ±âÁ¸ÀÇ °³Èä ¼ö¼ú¿¡ ºñÇØ ¼ö¼ú ¿Ü»ó ¹× ȸº¹ ½Ã°£À» ÁÙÀ̰í ÇÕº´Áõ À§ÇèÀ» ÁÙÀÌ¸ç ¼ö¼ú ÈÄ »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ¹ß°ß ¹æ¹ýÀÌ °³¼±µÇ°í ´õ ¸¹Àº Æó¾ÏÀÌ ¼ö¼ú °¡´ÉÇÑ ´Ü°è¿¡¼­ Áø´ÜµÊ¿¡ µû¶ó Ä¡·á ¿ä¹ý¿¡¼­ ¼ö¼úÀÇ ¿ªÇÒÀº °è¼Ó È®´ëµÇ°í ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº Æó¾Ï ¼ö¼úÀ» ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

Æó¾Ï ¼ö¼úÀ» µÑ·¯½Ñ ȯ°æÀº º¸´Ù Á¤È®ÇÏ°í ´ú ħ½ÀÀûÀÎ ¼ö¼úÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ±â¼úÀÇ ¹ßÀüÀ¸·Î ¿ÏÀüÈ÷ ¹Ù²î¾ú½À´Ï´Ù. ·Îº¿ ¼ö¼ú°ú °°Àº ±â¼ú Çõ½ÅÀº ¿Ü°ú Àǻ翡°Ô ³ôÀº ¼ÕÀçÁÖ¿Í ÅëÁ¦·ÂÀ» Á¦°øÇÏ¿© °Ç°­ÇÑ Á¶Á÷À» º¸Á¸Çϸ鼭 º¹ÀâÇÑ ÇØºÎ¸¦ ¼öÇàÇϰí Á¾¾çÀ» Á¤È®ÇÏ°Ô Á¦°ÅÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¶ÇÇÑ ½Ç½Ã°£ CT ½ºÄµ ¹× Çü±¤ ¿µ»óÁø´Ü°ú °°Àº ¼ö¼ú Áß ¿µ»óÁø´Ü ±â¼úÀº Á¾¾çÀÇ À§Ä¡¿Í ÀýÁ¦ ´Ü¸éÀÇ Æò°¡ Á¤È®µµ¸¦ Çâ»ó½ÃÄÑ Ã¹ ¹øÂ° ¼ö¼ú¿¡¼­ ´õ ¸¹Àº ¾Ï Á¶Á÷À» È®½ÇÇÏ°Ô Á¦°ÅÇÒ ¼ö ÀÖ°Ô Çß½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ¿Ü°úÀû °³ÀÔÀÇ ¼º°ø·üÀ» ³ôÀÏ »Ó¸¸ ¾Æ´Ï¶ó ȯÀÚ¿¡°Ô ¹ÌÄ¡´Â ½ÅüÀû ¿µÇâÀ» ÃÖ¼ÒÈ­Çϰí ȸº¹ ½Ã°£À» ´ÜÃàÇÏ°í ¼ö¼ú ÈÄ ºÒÆíÇÔÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

Á¶±â ¹ß°ß°ú ¸ÂÃãÇü Ä¡·á´Â Æó¾Ï ¼ö¼ú °á°ú¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¥±î?

Á¶±â ¹ß°ß°ú ¸ÂÃã Ä¡·á Á¢±Ù¹ýÀº Æó¾Ï ¼ö¼ú °á°ú¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. °íÀ§Ç豺¿¡ ´ëÇÑ Àú¼±·® CT °Ë»çÀÇ °³¹ß·Î Æó¾ÏÀ» Á¶±â¿¡ Áø´ÜÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, ¼ö¼úÀû ÀýÁ¦°¡ °¡´ÉÇÏ°í ¿ÏÄ¡ °¡´É¼ºÀÌ ³ôÀº ´Ü°è¿¡¼­ Áø´ÜµÇ´Â °æ¿ì°¡ ¸¹¾ÆÁ³½À´Ï´Ù. ¶ÇÇÑ Á¾¾çÀÇ À¯ÀüÀû ÇÁ·ÎÆÄÀϸµÀ» ÅëÇØ Á¾¾çÀÇ Æ¯¼ºÀ» ÆÄ¾ÇÇÏ´Â ¸ÂÃãÀÇ·á´Â ¾î¶² ȯÀÚ°¡ ¼ö¼ú¿¡ ÀûÇÕÇÑÁö, È­Çпä¹ýÀ̳ª Ç¥ÀûÄ¡·á¿Í °°Àº Ãß°¡ Ä¡·á¿¡ ¾î¶»°Ô ¹ÝÀÀÇÒÁö¸¦ °áÁ¤ÇÏ´Â µ¥ ÀÖ¾î ºñ¾àÀûÀÎ ¹ßÀüÀ» ÀÌ·ç¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ÂÃãÇü Á¢±Ù¹ýÀº ¼ö¼úÀÇ È¿°ú¸¦ ±Ø´ëÈ­ÇÏ°í ºÒÇÊ¿äÇÑ Ä¡·á¸¦ ÃÖ¼ÒÈ­ÇÏ´Â Ä¡·á °èȹÀ» ¼ö¸³ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

Æó¾Ï ¼ö¼ú ½ÃÀåÀÇ ¼ºÀåÀº ¿©·¯ °¡Áö ¿äÀÎÀ¸·Î ÀÎÇØ ¹ß»ýÇÑ´Ù

Æó¾Ï ¼ö¼ú ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ¹ß°ß ¹æ¹ýÀÇ °³¼±, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÃÖ¼Òħ½À ¼ö¼ú ¹× ·Îº¿ º¸Á¶ ¼ö¼ú°ú °°Àº ¼ö¼ú ±â¹ýÀÇ Çõ½ÅÀº ¼ö¼úÀÌ °¡´ÉÇÑ È¯ÀÚÀÇ ¹üÀ§¸¦ ³ÐÈ÷°í ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÏ¿© ¸¹Àº ȯÀڵ鿡°Ô ¼ö¼úÀÌ ´õ Çö½ÇÀûÀÎ ¼±ÅÃÀÌ µÉ ¼ö ÀÖµµ·Ï Çß½À´Ï´Ù. ¶ÇÇÑ, °ËÁø ÇÁ·Î±×·¥ÀÇ °­È­´Â ¼ö¼úÀû °³ÀÔÀÌ °¡Àå È¿°úÀûÀÎ Á¶±â ¾ÏÀÇ ¹ß°ßÀ» ´Ã¸®´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Æó¾ÏÀÇ À¯ÀüÀû ±â¹Ý¿¡ ´ëÇÑ ÀÌÇØµµ°¡ ³ô¾ÆÁü¿¡ µû¶ó °³ÀÎÈ­µÈ ¼ö¼úÀû Ä¡·á°¡ º¸ÆíÈ­µÇ¾î º¸´Ù Ç¥ÀûÈ­µÇ°í È¿°úÀûÀÎ °³ÀÔÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Æó¾ÏÀÇ À§Çè°ú ¿¹¹æ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Æó¾Ï Ä¡·á¿¡¼­ ¼ö¼úÀû ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áö¼ÓÀûÀ¸·Î °ßÀÎÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿ªµ¿ÀûÀ̰í ÁøÈ­ÇÏ´Â ½ÃÀåÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÃÑ 111°³ ÁÖ¸ñ)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Lung Cancer Surgery Market to Reach US$8.3 Billion by 2030

The global market for Lung Cancer Surgery estimated at US$6.2 Billion in the year 2023, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2023-2030. Thoracotomy Procedure, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$5.8 Billion by the end of the analysis period. Growth in the Minimally Invasive Surgery segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 6.5% CAGR

The Lung Cancer Surgery market in the U.S. is estimated at US$1.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Lung Cancer Surgery Market - Key Trends & Drivers Summarized

Why Is Lung Cancer Surgery a Critical Component of Cancer Treatment Today?

Lung cancer remains one of the most prevalent and deadly cancers worldwide, making effective treatment modalities like surgery crucial in the fight against this disease. Surgery for lung cancer involves the removal of the tumor and surrounding lung tissue where cancer cells may have spread. This approach is generally most effective in the early stages of lung cancer, specifically non-small cell lung cancer (NSCLC), where the tumor is localized and operable. Advances in surgical techniques, including minimally invasive procedures such as video-assisted thoracic surgery (VATS) and robot-assisted surgery, have significantly improved outcomes for patients. These techniques reduce surgical trauma and recovery time, decrease the risk of complications, and can improve the quality of life post-surgery compared to traditional open surgery. As detection methods improve and more lung cancers are diagnosed at an operable stage, the role of surgery in treatment regimens continues to expand.

How Are Technological Advances Transforming Lung Cancer Surgery?

The landscape of lung cancer surgery has been transformed by technological advancements that allow for more precise and less invasive procedures. Innovations such as robotic surgery provide surgeons with enhanced dexterity and control, enabling them to perform complex dissections and remove tumors with high precision while preserving healthy tissue. Furthermore, intraoperative imaging technologies like real-time CT scans and fluorescence imaging have improved the accuracy of tumor localization and the assessment of resection margins, ensuring that more of the cancerous tissue is removed during the initial surgery. These advancements not only increase the success rate of surgical interventions but also minimize the physical impact on patients, leading to faster recovery times and less postoperative discomfort.

What Impact Do Early Detection and Personalized Treatment Have on Lung Cancer Surgery Outcomes?

Early detection and personalized treatment approaches are significantly influencing outcomes in lung cancer surgery. The development of low-dose CT screening for high-risk individuals has led to earlier diagnosis of lung cancer, often at a stage when surgical resection is possible and more likely to be curative. Personalized medicine, which involves genetic profiling of tumors to understand their unique characteristics, has also made strides in determining which patients are good candidates for surgery and how they might best respond to additional treatments such as chemotherapy or targeted therapy. This tailored approach helps in strategizing treatment plans that maximize the efficacy of surgery and minimize unnecessary treatments, thereby improving overall patient survival and quality of life.

Growth in the Lung Cancer Surgery Market Is Driven by Several Factors

The growth in the lung cancer surgery market is driven by several factors, encompassing technological advancements, improved detection methods, and an increased emphasis on personalized medicine. Technological innovations in surgical techniques, including minimally invasive and robotic-assisted surgeries, have broadened the range of operable cases and improved patient outcomes, making surgery a more viable option for many patients. Enhanced screening programs have also played a critical role, as they increase the number of early-stage cancers identified, where surgical intervention can be most beneficial. Additionally, as understanding of the genetic basis of lung cancer improves, personalized surgical treatments are becoming more prevalent, allowing for more targeted and effective interventions. These developments, combined with a growing awareness of lung cancer risks and prevention, continue to drive the demand for surgical solutions in the treatment of lung cancer, reflecting a dynamic and evolving marketplace.

Select Competitors (Total 111 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â